Argenx Se (ARGX) Current Assets (2015 - 2026)
Argenx Se's (ARGX) quarterly Current Assets came in at $8.1 billion in Q2 2026, down 99.86% YoY from $5829.7 billion in Q2 2025, and up 16.94% on a QoQ basis from $6.9 billion in Q4 2025.
Argenx Se (ARGX) Current Assets (2015 - 2026) Analysis & Trends
Argenx Se (ARGX) has 12 years of Current Assets data on file, last reported at $8.1 billion in Q2 2026.
- Quarterly Current Assets fell 99.86% year-over-year to $8.1 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $8.1 billion (down 99.86% YoY) and the FY2025 annual result came in at $6.9 billion, up 41.28% from the prior year.
- Current Assets improved to $8.1 billion in Q2 2026, from $6.9 billion in the prior quarter.
- In the past five years, Current Assets ranged from a high of $5829.7 billion in Q2 2025 to a low of $2.7 billion in Q2 2023.
- A 5-year average of $651.8 billion and a median of $4.3 billion in 2024 frame the typical range for Current Assets.
- Annual changes were most pronounced in 2025 — Current Assets soared 136626.76% — and 2026, when it slumped 99.86%.
- Tracing ARGX's Current Assets over 5 years: stood at $2.8 billion in 2022, then soared by 48.65% to $4.1 billion in 2023, then climbed by 18.41% to $4.9 billion in 2024, then jumped by 41.28% to $6.9 billion in 2025, then gained by 16.94% to $8.1 billion in 2026.
- The last three Current Assets figures came in at $8.1 billion (Q2 2026), $6.9 billion (Q4 2025), and $5829.7 billion (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 4.74 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 8.07 Bn |
| Dec 31, 2025 | 6.90 Bn |
| Jun 30, 2025 | 5,829.74 Bn |
| Dec 31, 2024 | 4.88 Bn |
| Jun 30, 2024 | 4.26 Bn |
| Dec 31, 2023 | 4.12 Bn |
| Jun 30, 2023 | 2.69 Bn |
| Dec 31, 2022 | 2.77 Bn |
| Jun 30, 2022 | 2.93 Bn |
| Dec 31, 2021 | 2.54 Bn |
| Jun 30, 2021 | 2.86 Bn |
| Dec 31, 2020 | 2.00 Bn |
| Jun 30, 2020 | 2.16 Bn |
| Dec 31, 2019 | 1.52 Bn |
| Jun 30, 2019 | 1.08 Bn |
| Dec 31, 2018 | 653.38 Mn |
| Jun 30, 2018 | 424.58 Mn |
| Dec 31, 2017 | 431.89 Mn |
| Jun 30, 2017 | 200.02 Mn |
| Dec 31, 2016 | 109.91 Mn |